Tracheal relaxing effects and beta 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues.
Tracheal relaxing effects and beta 2-selectivity of TA-2005 were investigated by functional experiments and radioligand binding assay in guinea pigs in comparison with those of other beta-agonists, isoproterenol, procaterol, formoterol and salbutamol. The relaxing activity of TA-2005 on histamine-induced contraction in the isolated trachea was most potent among the five agonists, and it was blocked by a beta 2-selective antagonist (ICI 118,551) but not by a beta 1-selective antagonist (bisoprolol). The potency of the relaxing effect was in the order of TA-2005 (pD2 = 9.79) greater than formoterol greater than procaterol greater than isoproterenol greater than or equal to salbutamol. The positive chronotropic effect of TA-2005 was similar to that of isoproterenol; and it was more potent than those of formoterol, procaterol and salbutamol in the isolated atria. The selectivity for tracheal muscle to atria of these agonists were in the order of procaterol greater than greater than or equal to formoterol greater than TA-2005 greater than salbutamol much greater than isoproterenol. A radioligand binding experiment using guinea pig lung and cardiac ventricle as beta 2- and beta 1-adrenoceptor sources, respectively, has also demonstrated that TA-2005 possesses extremely high affinity (IC50 = 1.04 nM) and selectivity (38-fold) to beta 2-adrenoceptors. By addition of GTP, the competition curve of [125I]iodocyanopindolol shifted rightward, indicating the agonist property. These results confirmed that TA-2005 is a highly beta 2-selective agonist that exerts a potent tracheal relaxing effect.
Kikkawa
H
H
Biological Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, Japan.
Naito
K
K
Ikezawa
K
K
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000420:Albuterol / Q000494:pharmacology; D000662:Amphetamines / Q000494:pharmacology*; D000818:Animals; D001993:Bronchodilator Agents / Q000494:pharmacology*; D004983:Ethanolamines / Q000494:pharmacology; D000068759:Formoterol Fumarate; D006160:Guanosine Triphosphate / Q000494:pharmacology; D006168:Guinea Pigs; D006352:Heart Ventricles / Q000378:metabolism; D006632:Histamine / Q000494:pharmacology; D006912:Hydroxyquinolines / Q000494:pharmacology*; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes; D020120:Iodocyanopindolol; D007545:Isoproterenol / Q000494:pharmacology; D007700:Kinetics; D008168:Lung / Q000378:metabolism; D008297:Male; D008566:Membranes / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects; D009126:Muscle Relaxation / Q000187:drug effects*; D010869:Pindolol / Q000031:analogs & derivatives / Q000378:metabolism; D017265:Procaterol; D015363:Quinolones / Q000494:pharmacology*; D011869:Radioligand Assay; D011943:Receptors, Adrenergic, beta / Q000145:classification / Q000378:metabolism; D014132:Trachea / Q000187:drug effects* / Q000502:physiology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000662:Amphetamines; D001993:Bronchodilator Agents; D004983:Ethanolamines; D006912:Hydroxyquinolines; D007457:Iodine Radioisotopes; D015363:Quinolones; D011943:Receptors, Adrenergic, beta; D006632:Histamine; D020120:Iodocyanopindolol; D006160:Guanosine Triphosphate; C074413:carmoterol; D010869:Pindolol; D007545:Isoproterenol; D000420:Albuterol; D000068759:Formoterol Fumarate; D017265:Procaterol